Vasomedical raises $2.5m:
This article was originally published in Clinica
Westbury, New York-based Vasomedical has closed a $2.5m round of private financing. It will use the proceeds for marketing efforts relating to the use of its EECP external counterpulsation therapy as treatment for congestive heart failure patients; for activities to expand reimbursement coverage with third-party payers; and for the further promotion of EECP therapy in the current refractory angina market segment. The EECP system is designed as a noninvasive method to increase circulation in the heart and restore systemic vascular function.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.